Guillain-Barré syndrome in Mexico: An updated review amid the coronavirus cisease 2019 ERA
Guillain-Barré syndrome (GBS) is the most frequent cause of acute flaccid paralysis and if not diagnosed and treated timely, a significant cause of long-term disability. Incidence in Latin America ranges from 0.71 to 7.63 cases/100,000 person-years. Historically, GBS has been linked to infections (m...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Permanyer
2022-07-01
|
| Series: | Revista de Investigación Clínica |
| Subjects: | |
| Online Access: | https://www.clinicalandtranslationalinvestigation.com/frame_esp.php?id=421 |
| _version_ | 1811237204713799680 |
|---|---|
| author | Javier A. Galnares-Olalde Juan C. López-Hernández Miguel García-Grimshaw Sergio I. Valdés-Ferrer María E. Briseño-Godínez Adib J. de-Sarachaga Marco A. Alegría-Loyola Anna Bazán-Rodriguez Eunice Martínez-Jiménez Edwin S. Vargas-Cañas |
| author_facet | Javier A. Galnares-Olalde Juan C. López-Hernández Miguel García-Grimshaw Sergio I. Valdés-Ferrer María E. Briseño-Godínez Adib J. de-Sarachaga Marco A. Alegría-Loyola Anna Bazán-Rodriguez Eunice Martínez-Jiménez Edwin S. Vargas-Cañas |
| author_sort | Javier A. Galnares-Olalde |
| collection | DOAJ |
| description | Guillain-Barré syndrome (GBS) is the most frequent cause of acute flaccid paralysis and if not diagnosed and treated timely, a significant cause of long-term disability. Incidence in Latin America ranges from 0.71 to 7.63 cases/100,000 person-years. Historically, GBS has been linked to infections (mainly gastrointestinal by Campylobacter jejuni) and vaccines (including those against severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]); however, a trigger cannot be detected in most cases. Regarding SARS-CoV-2, epidemiological studies have found no association with its development. Acute motor axonal neuropathy is the most common electrophysiological variant in Mexico and Asian countries. Intravenous immunoglobulin or plasma exchanges are still the treatment cornerstones. Mortality in Mexico can be as high as 12%. Avances in understanding the drivers of nerve injury in GBS that may provide the basis for developing targeted therapies have been made during the past decade; despite them, accurate criteria for selecting patients requiring acute treatment, prognostic biomarkers, and novel therapies are still needed. The newly-developed vaccines against SARS-CoV-2 have raised concerns regarding the potential risk for developing GBS. In the midst of coronavirus disease 2019 and vaccination campaigns against SARS-CoV-2, this review discusses the epidemiology, clinical presentation, management, and outcomes of GBS in Mexico.
|
| first_indexed | 2024-04-12T12:22:38Z |
| format | Article |
| id | doaj.art-4c38b2c46a2746e18ecfde049e3d602a |
| institution | Directory Open Access Journal |
| issn | 0034-8376 2564-8896 |
| language | English |
| last_indexed | 2024-04-12T12:22:38Z |
| publishDate | 2022-07-01 |
| publisher | Permanyer |
| record_format | Article |
| series | Revista de Investigación Clínica |
| spelling | doaj.art-4c38b2c46a2746e18ecfde049e3d602a2022-12-22T03:33:15ZengPermanyerRevista de Investigación Clínica0034-83762564-88962022-07-0174310.24875/RIC.22000006Guillain-Barré syndrome in Mexico: An updated review amid the coronavirus cisease 2019 ERAJavier A. Galnares-Olalde0Juan C. López-Hernández1Miguel García-Grimshaw2Sergio I. Valdés-Ferrer3María E. Briseño-Godínez4Adib J. de-Sarachaga5Marco A. Alegría-Loyola6Anna Bazán-Rodriguez7Eunice Martínez-Jiménez8Edwin S. Vargas-Cañas9Neuromuscular Diseases Department, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, MexicoNeuromuscular Diseases Department, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, MexicoDepartment of Neurology and Psychiatry, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, MexicoDepartment of Neurology and Psychiatry, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; Feinstein Institutes for Medical Research, Manhasset, NY, USANeuromuscular Diseases Department, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, MexicoNeuromuscular Diseases Department, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, MexicoNeurology Department, Centro Médico ABC, Mexico City, MexicoNeuromuscular Diseases Department, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, MexicoNeuromuscular Diseases Department, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, MexicoNeuromuscular Diseases Department, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, MexicoGuillain-Barré syndrome (GBS) is the most frequent cause of acute flaccid paralysis and if not diagnosed and treated timely, a significant cause of long-term disability. Incidence in Latin America ranges from 0.71 to 7.63 cases/100,000 person-years. Historically, GBS has been linked to infections (mainly gastrointestinal by Campylobacter jejuni) and vaccines (including those against severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]); however, a trigger cannot be detected in most cases. Regarding SARS-CoV-2, epidemiological studies have found no association with its development. Acute motor axonal neuropathy is the most common electrophysiological variant in Mexico and Asian countries. Intravenous immunoglobulin or plasma exchanges are still the treatment cornerstones. Mortality in Mexico can be as high as 12%. Avances in understanding the drivers of nerve injury in GBS that may provide the basis for developing targeted therapies have been made during the past decade; despite them, accurate criteria for selecting patients requiring acute treatment, prognostic biomarkers, and novel therapies are still needed. The newly-developed vaccines against SARS-CoV-2 have raised concerns regarding the potential risk for developing GBS. In the midst of coronavirus disease 2019 and vaccination campaigns against SARS-CoV-2, this review discusses the epidemiology, clinical presentation, management, and outcomes of GBS in Mexico. https://www.clinicalandtranslationalinvestigation.com/frame_esp.php?id=421Guillain-Barré syndrome. Polyneuropathy. Intravenous immunoglobulin. Plasma exchange. Areflexic flaccid paralysis. Anti-ganglioside antibodies. |
| spellingShingle | Javier A. Galnares-Olalde Juan C. López-Hernández Miguel García-Grimshaw Sergio I. Valdés-Ferrer María E. Briseño-Godínez Adib J. de-Sarachaga Marco A. Alegría-Loyola Anna Bazán-Rodriguez Eunice Martínez-Jiménez Edwin S. Vargas-Cañas Guillain-Barré syndrome in Mexico: An updated review amid the coronavirus cisease 2019 ERA Revista de Investigación Clínica Guillain-Barré syndrome. Polyneuropathy. Intravenous immunoglobulin. Plasma exchange. Areflexic flaccid paralysis. Anti-ganglioside antibodies. |
| title | Guillain-Barré syndrome in Mexico: An updated review amid the coronavirus cisease 2019 ERA |
| title_full | Guillain-Barré syndrome in Mexico: An updated review amid the coronavirus cisease 2019 ERA |
| title_fullStr | Guillain-Barré syndrome in Mexico: An updated review amid the coronavirus cisease 2019 ERA |
| title_full_unstemmed | Guillain-Barré syndrome in Mexico: An updated review amid the coronavirus cisease 2019 ERA |
| title_short | Guillain-Barré syndrome in Mexico: An updated review amid the coronavirus cisease 2019 ERA |
| title_sort | guillain barre syndrome in mexico an updated review amid the coronavirus cisease 2019 era |
| topic | Guillain-Barré syndrome. Polyneuropathy. Intravenous immunoglobulin. Plasma exchange. Areflexic flaccid paralysis. Anti-ganglioside antibodies. |
| url | https://www.clinicalandtranslationalinvestigation.com/frame_esp.php?id=421 |
| work_keys_str_mv | AT javieragalnaresolalde guillainbarresyndromeinmexicoanupdatedreviewamidthecoronaviruscisease2019era AT juanclopezhernandez guillainbarresyndromeinmexicoanupdatedreviewamidthecoronaviruscisease2019era AT miguelgarciagrimshaw guillainbarresyndromeinmexicoanupdatedreviewamidthecoronaviruscisease2019era AT sergioivaldesferrer guillainbarresyndromeinmexicoanupdatedreviewamidthecoronaviruscisease2019era AT mariaebrisenogodinez guillainbarresyndromeinmexicoanupdatedreviewamidthecoronaviruscisease2019era AT adibjdesarachaga guillainbarresyndromeinmexicoanupdatedreviewamidthecoronaviruscisease2019era AT marcoaalegrialoyola guillainbarresyndromeinmexicoanupdatedreviewamidthecoronaviruscisease2019era AT annabazanrodriguez guillainbarresyndromeinmexicoanupdatedreviewamidthecoronaviruscisease2019era AT eunicemartinezjimenez guillainbarresyndromeinmexicoanupdatedreviewamidthecoronaviruscisease2019era AT edwinsvargascanas guillainbarresyndromeinmexicoanupdatedreviewamidthecoronaviruscisease2019era |